Treating HCV After Liver Transplantation



Hepatitis C-related liver disease remains the number one indication for liver transplantation in the United States, and recurrent hepatitis C infection after liver transplantation approaches 100%. The past experiences in the management of recurrent hepatitis C have led to the current recommended anti-viral treatment with ribavirin and pegylated interferon. In this chapter we address the past, present, and future therapies and treatment strategies for recurrent hepatitis C after liver transplantation. The particular focus addresses current therapy, including monitoring for recurrence, timing of treatment, anti-viral dosing, adjuvant therapy with epogen analogs and granulocyte-stimulating factor, identifying factors influencing response to therapy, patient outcomes, and cost effectiveness of therapy. Also addressed in this chapter are special considerations in patients with viral co-infection with human immunodeficiency virus (HIV) or cytomegalovirus (CMV), as well as the possibility of treating patients who fail anti-viral therapy, and liver retransplantation for recurrent cirrhosis. Future therapies for hepatitis C remain an intense area of research, particularly the use of protease inhibitors (telaprevir and boceprevir) in conjunction with pegylated interferon and ribavirin; however, there are special considerations for liver transplant patients, and their effectiveness among this population remains to be observed.


Hepatitis C recurrence Liver transplantation Antiviral therapy 


  1. 1.
    Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol. 2010;199:1–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Mukherjee S, Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology. 2008;134:1777–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Prieto M, Berenguer M, Rimola A, et al. Liver transplantation in hepatitis C. A Spanish multi-centre experience. Eur J Gastroenterol Hepatol. 1998;10:771–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol. 2005;42:448.PubMedCrossRefGoogle Scholar
  6. 6.
    Berenguer M, Prieto M, Rayon JM. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Verna EC, De Martin E, Burra P, et al. The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation. Am J Transplant. 2009;9:1398–405.PubMedCrossRefGoogle Scholar
  8. 8.
    Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.PubMedCrossRefGoogle Scholar
  12. 12.
    Gane EJ, Naoumov NV, Qian KP, Williams R, et al. Longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110:167–77.PubMedCrossRefGoogle Scholar
  13. 13.
    Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21:459–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat. 2007;14 Suppl 1:89–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002;8:362–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009;9:1707–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Kuo A, Terrault NA. Management of Hepatitis C in Liver Transplant Recipients. Am J Transplant. 2006;6(3):449–58.Google Scholar
  20. 20.
    Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14 Suppl 2:S45–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Bahra M, Neumann UP, Jacob D, et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc. 2005;37(4):1700–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999;5(4 Suppl 1):S107.PubMedGoogle Scholar
  23. 23.
    Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation. 2006;82:579–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplant. 2006;12:1464–72.CrossRefGoogle Scholar
  25. 25.
    McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006;6(7):1578–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Veldt BJ, Poterucha JJ, Watt KD, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009;9:1406–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transplant. 2006;12:134–9.CrossRefGoogle Scholar
  29. 29.
    Peek R, Reddy KR. Hepatitis C virus-infected donors in liver transplantation. Gastroenterology. 2007;133:381–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection Hepatology 2011;53(1):317–24.
  31. 31.
    Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 1994;106:994–9.PubMedGoogle Scholar
  32. 32.
    Verna EC, Brown Jr RS. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis. 2008;12:637–59.PubMedCrossRefGoogle Scholar
  33. 33.
    Bownik H, Saab S. The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int. 2010;30:19–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Singh N, Gayowski T, Wagener MM, Marino IR. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation. 1999;15(67):69–72.CrossRefGoogle Scholar
  35. 35.
    Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001;33:1355–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Chalasani N, Manzarbeitia C, Ferenci P, et al. Interferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–98.PubMedCrossRefGoogle Scholar
  37. 37.
    Kuo A, Tan V, Lan B, et al. Long-term histological effects on preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl. 2008;14(10):1491–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004;78(9):1308–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998;28(3):831–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Riediger C, Berberat PO, Sauer P. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant. 2007;22 Suppl 8:viii37–46.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–99.PubMedCrossRefGoogle Scholar
  42. 42.
    Zimmerman T, Bocher W, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon a-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007;20(7):583–90.CrossRefGoogle Scholar
  43. 43.
    Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003;124(3):642–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Shergill A, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Translant. 2005;5(1):118–24.CrossRefGoogle Scholar
  45. 45.
    Walter T, Dumortier J, Guillaud O. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transpl. 2007;7(1):177–84.CrossRefGoogle Scholar
  46. 46.
    Neff GW, Montalbano M, O’Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation. 2004;78:1303–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation. 2006;82:43–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Gurusamy KS, Osmani B, Xirouchakis E, et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2009;(1):CD006803.Google Scholar
  49. 49.
    Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology. 1994;20:773–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Gane EJ, Lo SK, Riordan SM, et al. Randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology. 1998;27:1403–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, et al. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc. 2010;42:666–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Samuel D, Hepatitis C. interferon, and risk of rejection after liver transplantation. Liver Transpl. 2004;10(7):868–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459–65.PubMedCrossRefGoogle Scholar
  54. 54.
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.PubMedCrossRefGoogle Scholar
  55. 55.
    Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007;13:1100–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Cash WJ, Patterson K, Callender ME, McDougall NI. Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients. J Viral Hepatol. 2010;17:269–73.CrossRefGoogle Scholar
  57. 57.
    Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17–27.PubMedCrossRefGoogle Scholar
  58. 58.
    Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant. 2006;6:2348–55.PubMedCrossRefGoogle Scholar
  59. 59.
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362(9401):2095–100.PubMedCrossRefGoogle Scholar
  60. 60.
    Cardoso AC et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52(5):652–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009;43(7):661–71.PubMedCrossRefGoogle Scholar
  62. 62.
    Bizollon T, Ahmed SN, Radenne S, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut. 2003;52:283–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:199–207.PubMedCrossRefGoogle Scholar
  64. 64.
    Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679–87.PubMedCrossRefGoogle Scholar
  65. 65.
    Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant. 2005;5:1909–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–84.PubMedGoogle Scholar
  67. 67.
    Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patientswith recurrent chronic hepatitis C. Am J Transplant. 2005;5:1909–13.PubMedCrossRefGoogle Scholar
  69. 69.
    De Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation. 2001;71:678–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl. 2002;8:449–57.PubMedCrossRefGoogle Scholar
  71. 71.
    Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16:748–59.PubMedGoogle Scholar
  72. 72.
    Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults coinfected with HIV. Transplantation. 2001;72:1684–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Radecke K, Fruhauf NR, Miller M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int. 2005;25:101–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 2004;10:1271–8.PubMedCrossRefGoogle Scholar
  75. 75.
    de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983–93.PubMedCrossRefGoogle Scholar
  76. 76.
    Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency, virus-infected liver transplant recipients. J Infect Dis. 2003;188:1412–20.PubMedCrossRefGoogle Scholar
  77. 77.
    Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant. 2007;7:448–53.PubMedCrossRefGoogle Scholar
  78. 78.
    Joshi S, Regenstein F. Liver transplant patients with hepatitis C who do not respond to pegylated interferon plus ribavirin do respond to consensus interferon plus ribavirin. Am J Gastroenterol. 2007;102:S223.Google Scholar
  79. 79.
    Ghabril M, Dickson RC, Lucas J, et al. Consensus interferon therapy for hepatitis C recurrence after pegylated interferon failure post liver transplant. Hepatology. 2007;46:478A.Google Scholar
  80. 80.
    Bellido CB, Martínez JM, Gómez LM, et al. Indications for and survival after liver retransplantation. Transplant Proc. 2010;42:637–40.PubMedCrossRefGoogle Scholar
  81. 81.
    Markmann J, Markowitz JS, Yersiz H, et al. Long-term survival after retransplantation of the liver. Ann Surg. 1997;226:408–18.PubMedCrossRefGoogle Scholar
  82. 82.
    McCashland T, Watt K, Lyden E. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007;13:1246–53.PubMedCrossRefGoogle Scholar
  83. 83.
    Lang L. Combination therapy with telaprevir and pegylated interferon suppresses both wild-type and resistant hepatitis C virus. Gastroenterology. 2007;132:5–6.Google Scholar
  84. 84.
    Sarrazin C et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–77.PubMedCrossRefGoogle Scholar
  85. 85.
    Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine proteaseinhibitor in vitro. Antimicrob Agents Chemother. 2004;48:2260–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49:163–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Marcellin P, Forns X, Goeser T, et al. Virological analysis of patients receivingtelaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208. Hepatology. 2009;50 Suppl 1:395.Google Scholar
  89. 89.
    Benhamou Y, Moussalli J, Ratziu V, et al. Results of a prove of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol. 2009;50 Suppl 1:6.CrossRefGoogle Scholar
  90. 90.
    McHutchison JG, Manns MP, Muir AJ. et al; Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.PubMedCrossRefGoogle Scholar
  91. 91.
    Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of MedicineUniversity of California at Los AngelesLos AngelesUSA
  2. 2.Department of Surgery, Pfleger Liver InstituteUniversity of California at Los AngelesLos AngelesUSA

Personalised recommendations